<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10604732</article-id><article-id pub-id-type="pmc">2362979</article-id><article-id pub-id-type="pii">6690325</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mitry</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Baudin</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Ducreux</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sabourin</surname><given-names>J-C</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Rufi&#x000e9;</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Aparicio</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lasser</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">5</xref></contrib><contrib contrib-type="author"><name><surname>Elias</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">5</xref></contrib><contrib contrib-type="author"><name><surname>Duvillard</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Schlumberger</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Gastroenterology, <label>2</label>Nuclear Medicine, <label>3</label>Pathology, <label>4</label>Pneumology and<label>5</label>Surgery, Institut Gustave Roussy, Villejuif, France</aff><aff id="aff6"><label>6</label>Department of Gastroenterology and Digestive Oncology, H&#x000f4;pital Ambroise Par&#x000e9;, Boulogne, France</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: </corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>1999</year></pub-date><volume>81</volume><issue>8</issue><fpage>1351</fpage><lpage>1355</lpage><history><date date-type="received"><day>05</day><month>11</month><year>1998</year></date><date date-type="rev-recd"><day>08</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>17</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m<sup>&#x02013;2</sup> day<sup>&#x02013;1</sup> for 3 days and cisplatin 100 mg m<sup>&#x02013;2</sup> on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4&#x00025;) had a partial response for 8.5 months. Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5&#x00025; (four complete and 13 partial responses); the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival 8.9 months. Haematological grade 3&#x02013;4 toxicity was observed in 60&#x00025; of the cases with one treatment-related death, digestive grade 3&#x02013;4 toxicity in 40&#x00025; and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6&#x00025;, 14&#x00025;, 72&#x00025; respectively and no grade &#x0003e;1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20&#x00025; confirming that new therapeutic strategies have to be developed. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>neuroendocrine carcinoma</kwd><kwd>treatment</kwd><kwd>retrospective study</kwd></kwd-group></article-meta></front></article>


